Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo completes Indevus Pharmaceuticals buyout

This article was originally published in Scrip

Executive Summary

Endo Pharmaceuticals has completed its $370 million acquisition of Indevus Pharmaceuticals. Indevus' common stock stopped trading on March 23rd, 2009 around 11 weeks after the $4.50 per share bid was made (scripnews.com, January 6th, 2009). An additional $3.00 per share is dependent on regulatory and sales milestones.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC001078

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel